行情

MYGN

MYGN

万基遗传
NASDAQ

实时行情|Nasdaq Last Sale

25.11
+0.11
+0.44%
已收盘, 16:06 11/21 EST
开盘
25.06
昨收
25.00
最高
25.33
最低
24.82
成交量
45.12万
成交额
--
52周最高
48.40
52周最低
20.10
市值
18.68亿
市盈率(TTM)
-119.7996
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

MYGN 新闻

  • CLASS ACTION UPDATE for SNDL, MYGN, DOMO and ET: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  • GlobeNewswire.17小时前
  • SHAREHOLDER ALERT: MTCH MYGN TWTR CGC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
  • GlobeNewswire.18小时前
  • MYGN ALERT: Zhang Investor Law Reminds Investors of NOVEMBER 26 Deadline in Securities Class Action Lawsuit Against Myriad Genetics, Inc. MYGN
  • GlobeNewswire.22小时前
  • The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADTN, MTCH, MYGN and UA
  • GlobeNewswire.23小时前

更多

所属板块

医疗设备、用品及经销
-0.06%
医疗设备和用品
-0.17%

热门股票

名称
价格
涨跌幅

MYGN 简况

Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.
展开

Webull提供Myriad Genetics, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。